Table 3 Patient-reported outcomes (SF-12, MRC scale, and 6 MWD)
Variables | Patients treated with AVAPS | Control group | Treatment Effect (95% CI) 6 months–baseline | P-Value | ||
|---|---|---|---|---|---|---|
Baseline | After 6 month | Baseline | After 6 month | |||
SF-36 Scales # | ||||||
Vitality | 55.2 ± 16.1 | 64.3 ± 17.5 | 56.1 ± 17.3 | 60.5 ± 16.2 | 5.4(1.4 to 9.3) | 0.001* |
General health | 56.3 ± 20.5 | 61.3 ± 16.7 | 57.6 ± 19.2 | 58.4 ± 20.2 | 8.2(3.2 to 11.7) | 0.001* |
Physical functioning | 72.4 ± 23.8 | 77.5 ± 21.5 | 69.3 ± 24.2 | 69.6 ± 22.1 | 5.5(1.1 to 9.8) | 0.001* |
Bodily pain | 62.3 ± 23.2 | 65.5 ± 22.4 | 63.7 ± 23.6 | 66.7 ± 20.8 | 3.1 (3.4 to 8.8 | 0.002* |
Emotional Role Functioning | 80.6 ± 22.5 | 83.5 ± 24.7 | 79.0 ± 24.8 | 82.3 ± 20.7 | −0.5 (−6.8 to 5.3) | 0.321 |
Physical Role Functioning | 69.3 ± 23.3 | 73.5 ± 26.6 | 70.8 ± 23.7 | 73.2 ± 24.8 | 3.3(−5 to 6.6) | 0.001* |
Social Role Functioning | 79.6 ± 23.8 | 83.6 ± 24.7 | 80.8 ± 21.9 | 82.9 ± 25.8 | 1.6 (−3.8 to 6.4) | 0.143 |
Mental health | 74.4 ± 18.6 | 75.8 ± 12.8 | 75.6 ± 15.7 | 75.4 ± 15.4 | 1.2 (−1.7 to 6.9) | 0.543 |
PCSS | 45.3 ± 9.6 | 51.3 ± 8.4 | 44.1 ± 8.4 | 44.7 ± 7.2 | 3.7 (1.2 to 5.8) | 0.001* |
MCSS | 50.3 ± 10.8 | 53.5 ± 12.7 | 49.2 ± 11.8 | 52.7 ± 11.2 | 1.1 (−2.7 to 2.9) | 0.436 |
MRC scale # | 4.3 ± 0.5 | 3.1 ± 0.2 | 4.1 ± 0.7 | 4 ± 0.4 | 0.4(−0.2 to 3) | 0.213 |
6MWD, m # | 178.2 ± 24.3 | 260.5 ± 32.2 | 179.3 ± 32.1 | 255.2 ± 30.2 | 9.2(−1 to 15) | 0.001* |